Cognito Therapeutics
Cambridge
About Cognito Therapeutics
Cognito Therapeutics is a clinical-stage neurotechnology business focused on creating disease-modifying pharmaceutical methods for the treatment of neurodegenerative illnesses. Li-Huei Tsai and Ed Boyden, MIT Professors, and scientific founders, created its non-invasive neuromodulation platform. The Company's primary therapy is now being studied in a pivotal study for Alzheimer's Disease and has been designated as a Breakthrough Device by the FDA.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $321.8M
- Funding stage: Late Stage Venture
- Last round: Series C (Mar 2026)
- Website: cognitotx.com
- Phone: 857-201-5088
Industries & Categories
Biotechnology, Health Diagnostics, Medical Device, Neuroscience, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/cognito-therapeutics-4787 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.